Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Drop in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 134,793 shares, a decline of 14.3% from the March 15th total of 157,346 shares. Based on an average trading volume of 132,777 shares, the short-interest ratio is presently 1.0 days. Approximately 3.6% of the shares of the stock are short sold.

Hedge Funds Weigh In On Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. World Investment Advisors acquired a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 29,000 shares of the company’s stock, valued at approximately $38,000. World Investment Advisors owned 0.40% of Capstone Therapeutics as of its most recent SEC filing. Institutional investors own 2.55% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Capstone Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Capstone Therapeutics currently has an average rating of “Sell”.

Capstone Therapeutics Price Performance

CAPS opened at $0.40 on Friday. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.95 and a quick ratio of 0.35. The stock has a market capitalization of $3.67 million, a P/E ratio of -0.11 and a beta of -1.27. The company’s 50 day simple moving average is $0.61 and its 200-day simple moving average is $0.78. Capstone Therapeutics has a one year low of $0.38 and a one year high of $3.29.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.